Raymond James & Associates Xilio Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 38,825 shares of XLO stock, worth $27,565. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,825
Previous 38,825
-0.0%
Holding current value
$27,565
Previous $36,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding XLO
# of Institutions
34Shares Held
14MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.24 Million0.65% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3MShares$2.13 Million0.08% of portfolio
-
Morgan Stanley New York, NY1.52MShares$1.08 Million0.0% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.02 Million16.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$640,7970.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19.5M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...